Biotricity Inc. (OTCQB: BTCY) announced on March 12, 2025, the expansion of its intellectual property (IP) portfolio with 14 new patents. This brings the company's total to 15 issued patents, with an additional 14 patents pending.
The new patents focus on a multi-biometric device platform that can function in both patch and watch form factors. This adaptable design aims to ensure wider integration and compliance for diverse patient needs and clinical applications.
These innovations are expected to drive Biotricity’s next-generation device, enabling multiple diagnostic studies, such as cardiac and sleep studies, to be conducted simultaneously. This advancement streamlines diagnostic processes, potentially improving patient outcomes and reducing healthcare system burdens.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.